Skip to main content
Erschienen in: Cancer Causes & Control 7/2013

01.07.2013 | Original paper

Impact of hormone replacement therapy use on mammographic screening outcomes

verfasst von: Kerri R. Beckmann, Gelareh Farshid, David M. Roder, Janet E. Hiller, John W. Lynch

Erschienen in: Cancer Causes & Control | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to measure the impact of HRT use at the time of screening on rates of screen-detected invasive breast cancer (IBC) and ductal carcinoma in situ (DCIS), interval cancers and investigative procedures, within a well-established population-based mammography screening program.

Methods

Using South Australian BreastScreen data from 1998 to 2009 pertaining to 819,722 screening episodes, Poisson regression models were undertaken to estimate the incidence risk ratios (IRR) for various screening outcomes at both the first and subsequent screening rounds, among women who had been using HRT in the 6 months prior to screening compared with those who had not.

Results

Current HRT use was associated with increased risk of recall for assessment, biopsy procedures, and breast cancer diagnosis among BreastScreen participants. Risk of screen-detected breast cancer was increased at subsequent screening rounds (IRR = 1.30, 95 % confidence interval 1.18–1.34), but not at women’s first screening round (1.05, 0.88–1.25). This increased risk applied to IBC (1.35, 1.27–1.45), but not to DCIS (1.04, 0.89–1.23). Interval cancer risk was elevated among HRT users following both the first screen (1.77, 1.33–2.37) and subsequent screening episodes (1.92, 1.72–2.15).

Conclusions

Increased risks of recall, biopsy rates, screen-detected, and interval cancers among HRT users have important implications for population-based breast cancer screening programs. Our findings support the concept that HRT use may increase the growth of preexisting cancers. Lack of effect on DCIS could imply different etiology or time frames for DCIS and IBC development or increased transition from preinvasive to invasive disease due to HRT use.
Literatur
1.
Zurück zum Zitat Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253. doi:10.1001/jama.289.24.3243 PubMedCrossRef Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253. doi:10.​1001/​jama.​289.​24.​3243 PubMedCrossRef
3.
Zurück zum Zitat Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332PubMedCrossRef Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328–332PubMedCrossRef
4.
Zurück zum Zitat Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160. doi:10.1158/1055-9965.EPI-08-0435 PubMedCrossRef Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150–3160. doi:10.​1158/​1055-9965.​EPI-08-0435 PubMedCrossRef
5.
Zurück zum Zitat Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254–3263. doi:10.1001/jama.289.24.3254 PubMedCrossRef Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254–3263. doi:10.​1001/​jama.​289.​24.​3254 PubMedCrossRef
6.
Zurück zum Zitat Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonzalez CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128(1):144–156. doi:10.1002/ijc.25314 PubMedCrossRef Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonzalez CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128(1):144–156. doi:10.​1002/​ijc.​25314 PubMedCrossRef
7.
Zurück zum Zitat Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966. doi:10.1158/1055-9965.EPI-05-0762 PubMedCrossRef Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961–966. doi:10.​1158/​1055-9965.​EPI-05-0762 PubMedCrossRef
8.
Zurück zum Zitat Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118(12):3112–3117. doi:10.1002/ijc.21742 PubMedCrossRef Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118(12):3112–3117. doi:10.​1002/​ijc.​21742 PubMedCrossRef
9.
Zurück zum Zitat Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2012) Effect of protocol-related variables and women’s characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol 23(1):104–111. doi:10.1093/annonc/mdr032 PubMedCrossRef Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2012) Effect of protocol-related variables and women’s characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol 23(1):104–111. doi:10.​1093/​annonc/​mdr032 PubMedCrossRef
11.
Zurück zum Zitat Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8(1):29–34PubMedCrossRef Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8(1):29–34PubMedCrossRef
12.
Zurück zum Zitat Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14(5):1060–1064. doi:10.1158/1055-9965.EPI-04-0165 PubMedCrossRef Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14(5):1060–1064. doi:10.​1158/​1055-9965.​EPI-04-0165 PubMedCrossRef
13.
Zurück zum Zitat Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477. doi:10.1136/bmj.329.7464.477 PubMedCrossRef Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477. doi:10.​1136/​bmj.​329.​7464.​477 PubMedCrossRef
14.
Zurück zum Zitat Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ 328(7451):1291–1292. doi:10.1136/bmj.328.7451.1291 PubMedCrossRef Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ 328(7451):1291–1292. doi:10.​1136/​bmj.​328.​7451.​1291 PubMedCrossRef
15.
Zurück zum Zitat Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF (2006) Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15(10):1856–1862. doi:10.1158/1055-9965.EPI-06-0290 PubMedCrossRef Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF (2006) Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15(10):1856–1862. doi:10.​1158/​1055-9965.​EPI-06-0290 PubMedCrossRef
16.
Zurück zum Zitat Litherland JC, Stallard S, Hole D, Cordiner C (1999) The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 54(5):285–288PubMedCrossRef Litherland JC, Stallard S, Hole D, Cordiner C (1999) The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 54(5):285–288PubMedCrossRef
20.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 350(9084):1047–1059CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 350(9084):1047–1059CrossRef
21.
23.
Zurück zum Zitat Roman R, Sala M, De La Vega M, Natal C, Galceran J, Gonzalez-Roman I, Baroja A, Zubizarreta R, Ascunce N, Salas D, Castells X (2011) Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening. Breast Cancer Res Treat 130(2):543–552. doi:10.1007/s10549-011-1581-4 PubMedCrossRef Roman R, Sala M, De La Vega M, Natal C, Galceran J, Gonzalez-Roman I, Baroja A, Zubizarreta R, Ascunce N, Salas D, Castells X (2011) Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening. Breast Cancer Res Treat 130(2):543–552. doi:10.​1007/​s10549-011-1581-4 PubMedCrossRef
24.
Zurück zum Zitat BreastScreen SA (2010) The impact of BreastScreen SA, 20 year report 1989–2008: with trend data for 1989–2004. Government of South Australia Adelaide BreastScreen SA (2010) The impact of BreastScreen SA, 20 year report 1989–2008: with trend data for 1989–2004. Government of South Australia Adelaide
25.
Zurück zum Zitat National Breast Cancer Centre (2002) Breast imaging: a guide for practice. National Breast Cancer Centre Camperdown NSW National Breast Cancer Centre (2002) Breast imaging: a guide for practice. National Breast Cancer Centre Camperdown NSW
26.
Zurück zum Zitat Australian Bureau of Statistics (2008) Information paper: an introduction to socio-economic indexes for areas (SEIFA), 2006 ABS, Canberra Australian Bureau of Statistics (2008) Information paper: an introduction to socio-economic indexes for areas (SEIFA), 2006 ABS, Canberra
27.
Zurück zum Zitat Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706PubMedCrossRef Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706PubMedCrossRef
28.
Zurück zum Zitat StataCorp (2010) Stata statistical software: release 12. StatCorp LP, College Station StataCorp (2010) Stata statistical software: release 12. StatCorp LP, College Station
29.
Zurück zum Zitat Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587. doi:10.1056/NEJMoa0807684 PubMedCrossRef Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573–587. doi:10.​1056/​NEJMoa0807684 PubMedCrossRef
30.
Zurück zum Zitat Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51(12):1277–1283PubMedCrossRef Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51(12):1277–1283PubMedCrossRef
33.
Zurück zum Zitat Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105–110PubMedCrossRef Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105–110PubMedCrossRef
34.
Zurück zum Zitat Sweeney KJ, Boran S, Fitzpatrick P, Merrigan AB, Moran R, Flanagan F, Kerin MJ (2009) Postmenopausal hormone therapy and prevalent round screening mammography. Int J Cancer 124(6):1490–1491. doi:10.1002/ijc.24081 PubMedCrossRef Sweeney KJ, Boran S, Fitzpatrick P, Merrigan AB, Moran R, Flanagan F, Kerin MJ (2009) Postmenopausal hormone therapy and prevalent round screening mammography. Int J Cancer 124(6):1490–1491. doi:10.​1002/​ijc.​24081 PubMedCrossRef
36.
Zurück zum Zitat Seradour B, Esteve J, Heid P, Jacquemier J (1999) Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen 6(2):99–102PubMedCrossRef Seradour B, Esteve J, Heid P, Jacquemier J (1999) Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen 6(2):99–102PubMedCrossRef
39.
40.
Zurück zum Zitat Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 21(7):1038–1048. doi:10.1158/1055-9965.EPI-12-0043 PubMedCrossRef Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 21(7):1038–1048. doi:10.​1158/​1055-9965.​EPI-12-0043 PubMedCrossRef
41.
Zurück zum Zitat Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281(22):2091–2097PubMedCrossRef Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281(22):2091–2097PubMedCrossRef
42.
Zurück zum Zitat Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274(2):137–142PubMedCrossRef Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274(2):137–142PubMedCrossRef
43.
Zurück zum Zitat Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657. doi:10.1001/jama.295.14.1647 PubMedCrossRef Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657. doi:10.​1001/​jama.​295.​14.​1647 PubMedCrossRef
44.
Zurück zum Zitat Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321. doi:10.1200/JCO.2003.05.151 PubMedCrossRef Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321. doi:10.​1200/​JCO.​2003.​05.​151 PubMedCrossRef
45.
Zurück zum Zitat Reeves GK, Pirie K, Green J, Bull D, Beral V (2011) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. doi:10.1002/ijc.26460 Reeves GK, Pirie K, Green J, Bull D, Beral V (2011) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. doi:10.​1002/​ijc.​26460
46.
Zurück zum Zitat Burrell HC, Pinder SE, Wilson AR, Evans AJ, Yeoman LJ, Elston CW, Ellis IO (1996) The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. Clin Radiol 51(4):277–281PubMedCrossRef Burrell HC, Pinder SE, Wilson AR, Evans AJ, Yeoman LJ, Elston CW, Ellis IO (1996) The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. Clin Radiol 51(4):277–281PubMedCrossRef
48.
Zurück zum Zitat Cui Y, Page DL, Lane DS, Rohan TE (2009) Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study. Breast Cancer Res Treat 114(1):113–120. doi:10.1007/s10549-008-9973-9 PubMedCrossRef Cui Y, Page DL, Lane DS, Rohan TE (2009) Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study. Breast Cancer Res Treat 114(1):113–120. doi:10.​1007/​s10549-008-9973-9 PubMedCrossRef
49.
Zurück zum Zitat Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL (2008) Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 100(8):563–571. doi:10.1093/jnci/djn075 PubMedCrossRef Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL (2008) Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 100(8):563–571. doi:10.​1093/​jnci/​djn075 PubMedCrossRef
50.
Zurück zum Zitat Maxwell CJ, Bancej CM, Snider J (2001) Predictors of mammography use among Canadian women aged 50–69: findings from the 1996/97 National population health survey. CMAJ 164(3):329–334PubMed Maxwell CJ, Bancej CM, Snider J (2001) Predictors of mammography use among Canadian women aged 50–69: findings from the 1996/97 National population health survey. CMAJ 164(3):329–334PubMed
51.
Zurück zum Zitat Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P, Beckmann K, Iosifidis P, Grieve L, Williamson L (2008) Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat 108(3):409–416. doi:10.1007/s10549-007-9609-5 PubMedCrossRef Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P, Beckmann K, Iosifidis P, Grieve L, Williamson L (2008) Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat 108(3):409–416. doi:10.​1007/​s10549-007-9609-5 PubMedCrossRef
Metadaten
Titel
Impact of hormone replacement therapy use on mammographic screening outcomes
verfasst von
Kerri R. Beckmann
Gelareh Farshid
David M. Roder
Janet E. Hiller
John W. Lynch
Publikationsdatum
01.07.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 7/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0221-1

Weitere Artikel der Ausgabe 7/2013

Cancer Causes & Control 7/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.